Last reviewed · How we verify

NCT05593861

Assessment of Enhanced Recovery After Surgery Implementation at Pediatric Surgery Practices in Mainland China

Completed Last updated 25 October 2022
What this trial tests

trial in ERAS in 66 participants. Completed in 21 July 2022.

Timeline
1 July 2021
Primary endpoint
1 July 2022
21 July 2022

Quick facts

Lead sponsorWeibing Tang
StatusCompleted
Study typeOBSERVATIONAL
Enrollment66
Start date1 July 2021
Primary completion1 July 2022
Estimated completion21 July 2022
Sites1 location across China

Conditions studied

Sponsor

Weibing Tang

Who can join

Eligibility, any sex, with ERAS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Enhanced recovery after surgery (ERAS) is a new mode to optimize perioperative management, the core of which is to reduce perioperative physiological and psychological trauma and stress damage, and accelerate postoperative rehabilitation. ERAS has been gradually introduced in pediatric surgery in recent years, however, there are limited reports on its overall implementation. We aimed to determine the popularity of ERAS among pediatric populations in mainland China.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for ERAS

Currently open trials in the same condition.

Other Weibing Tang trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05593861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing